



May 11, 2023

Recording of Extraordinary Losses in Non-consolidated Financial Results

Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; President and CEO: Takeshi Ito; hereinafter “Santen”) recorded extraordinary losses in the non-consolidated financial results as below.

1. Details of extraordinary losses

Santen has recorded JPY 77,779million of extraordinary losses in the non-consolidated financial results for the fiscal year ended March 31, 2023 (April 1, 2022 to March 31, 2023), as a loss on valuation of shares of subsidiaries and affiliates. This is due to the results of significant decline in the substantial value of shares of Santen Holdings EU B.V. (Netherlands), a consolidated subsidiary of Santen.

2. Impact on consolidated financial results

The above loss on valuation of shares of subsidiaries and affiliates did not impact consolidated results as it was eliminated in the consolidated financial statements.

Contact:

Guillaume Sakuma
Global Head of IR, IR Group
E-mail: ir@santen.com

About Santen

As a specialized company dedicated to eye health, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices, and its products now reach patients in over 60 countries and regions.

Toward realizing “WORLD VISION” (Happiness with Vision), the world Santen ultimately aspires to achieve, as a “Social Innovator”, Santen aims to reduce the social and economic opportunity loss of people around the world caused by eye diseases and defects by orchestrating and mobilizing key technologies and players around the world.

With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society.

For more information, please visit Santen’s website (<https://www.santen.com/en>).